Ben Van Calster1, Daan Nieboer2, Yvonne Vergouwe2, Bavo De Cock3, Michael J Pencina4, Ewout W Steyerberg2. 1. KU Leuven, Department of Development and Regeneration, Herestraat 49 Box 7003, 3000 Leuven, Belgium; Department of Public Health, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. Electronic address: ben.vancalster@med.kuleuven.be. 2. Department of Public Health, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. 3. KU Leuven, Department of Development and Regeneration, Herestraat 49 Box 7003, 3000 Leuven, Belgium. 4. Duke Clinical Research Institute, Duke University, 2400 Pratt Street, Durham, NC 27705, USA; Department of Biostatistics and Bioinformatics, Duke University, 2424 Erwin Road, Durham, NC 27719, USA.
Abstract
OBJECTIVE: Calibrated risk models are vital for valid decision support. We define four levels of calibration and describe implications for model development and external validation of predictions. STUDY DESIGN AND SETTING: We present results based on simulated data sets. RESULTS: A common definition of calibration is "having an event rate of R% among patients with a predicted risk of R%," which we refer to as "moderate calibration." Weaker forms of calibration only require the average predicted risk (mean calibration) or the average prediction effects (weak calibration) to be correct. "Strong calibration" requires that the event rate equals the predicted risk for every covariate pattern. This implies that the model is fully correct for the validation setting. We argue that this is unrealistic: the model type may be incorrect, the linear predictor is only asymptotically unbiased, and all nonlinear and interaction effects should be correctly modeled. In addition, we prove that moderate calibration guarantees nonharmful decision making. Finally, results indicate that a flexible assessment of calibration in small validation data sets is problematic. CONCLUSION: Strong calibration is desirable for individualized decision support but unrealistic and counter productive by stimulating the development of overly complex models. Model development and external validation should focus on moderate calibration.
OBJECTIVE: Calibrated risk models are vital for valid decision support. We define four levels of calibration and describe implications for model development and external validation of predictions. STUDY DESIGN AND SETTING: We present results based on simulated data sets. RESULTS: A common definition of calibration is "having an event rate of R% among patients with a predicted risk of R%," which we refer to as "moderate calibration." Weaker forms of calibration only require the average predicted risk (mean calibration) or the average prediction effects (weak calibration) to be correct. "Strong calibration" requires that the event rate equals the predicted risk for every covariate pattern. This implies that the model is fully correct for the validation setting. We argue that this is unrealistic: the model type may be incorrect, the linear predictor is only asymptotically unbiased, and all nonlinear and interaction effects should be correctly modeled. In addition, we prove that moderate calibration guarantees nonharmful decision making. Finally, results indicate that a flexible assessment of calibration in small validation data sets is problematic. CONCLUSION: Strong calibration is desirable for individualized decision support but unrealistic and counter productive by stimulating the development of overly complex models. Model development and external validation should focus on moderate calibration.
Authors: Laine E Thomas; Emily C O'Brien; Jonathan P Piccini; Ralph B D'Agostino; Michael J Pencina Journal: Eur Heart J Date: 2019-06-14 Impact factor: 29.983
Authors: Jie Yang; Mengru Zhang; Hongshik Ahn; Qing Zhang; Tony B Jin; Ien Li; Matthew Nemesure; Nandita Joshi; Haoran Jiang; Jeffrey M Miller; Robert Todd Ogden; Eva Petkova; Matthew S Milak; Mary Elizabeth Sublette; Gregory M Sullivan; Madhukar H Trivedi; Myrna Weissman; Patrick J McGrath; Maurizio Fava; Benji T Kurian; Diego A Pizzagalli; Crystal M Cooper; Melvin McInnis; Maria A Oquendo; Joseph John Mann; Ramin V Parsey; Christine DeLorenzo Journal: Hum Brain Mapp Date: 2018-08-16 Impact factor: 5.038
Authors: James J Jang; Manjushri Bhapkar; Adrian Coles; Sreekanth Vemulapalli; Christopher B Fordyce; Kerry L Lee; James E Udelson; Udo Hoffmann; Jean-Claude Tardif; W Schuyler Jones; Daniel B Mark; Vincent L Sorrell; Andrey Espinoza; Pamela S Douglas; Manesh R Patel Journal: Circ Cardiovasc Imaging Date: 2019-02 Impact factor: 7.792
Authors: Jejo D Koola; Sam B Ho; Aize Cao; Guanhua Chen; Amy M Perkins; Sharon E Davis; Michael E Matheny Journal: Dig Dis Sci Date: 2019-09-17 Impact factor: 3.199
Authors: Tessa S S Genders; Adrian Coles; Udo Hoffmann; Manesh R Patel; Daniel B Mark; Kerry L Lee; Ewout W Steyerberg; M G Myriam Hunink; Pamela S Douglas Journal: JACC Cardiovasc Imaging Date: 2017-06-14
Authors: Matthew J Feinstein; Robin M Nance; Daniel R Drozd; Hongyan Ning; Joseph A Delaney; Susan R Heckbert; Matthew J Budoff; William C Mathews; Mari M Kitahata; Michael S Saag; Joseph J Eron; Richard D Moore; Chad J Achenbach; Donald M Lloyd-Jones; Heidi M Crane Journal: JAMA Cardiol Date: 2017-02-01 Impact factor: 14.676